Pubblicazioni 2022

Web

Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C.
Cancer Treat Rev. 2022 Feb;103:102326. doi: 10.1016/j.ctrv.2021.102326. Epub 2021 Dec 23.
PMID: 35016085

FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Antoniotti C, Germani MM, Rossini D, Lonardi S, Pietrantonio F, Santini D, Marmorino F, Allegrini G, Daniel F, Raimondi A, Borelli B, Zaniboni A, Conca V, Abraham J, Spetzler D, Maiello E, Boccaccino A, Passardi A, Giordano M, Tamburini E, Korn MW, Masi G, Cremolini C. Eur J Cancer. 2022 Mar 30;167:23-31. doi: 10.1016/j.ejca.2022.02.031. Online ahead of print. PMID: 35366570

Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series
Hafliger E, Boccaccino A, Lapeyre-Prost A, Perret A, Gallois C, Antista M, Pilla L, Lecomte T, Scartozzi M, Soularue E, Salvatore L, Bourgeois V, Salati M, Tougeron D, Evesque L, Vaillant JN, El-Khoury R, Lonardi S, Cremolini C, Taieb J. Eur J Cancer. 2022 Apr 14;168:34-40. doi: 10.1016/j.ejca.2022.03.011. Online ahead of print. PMID: 35436675